[1] Nadolinskaia NI, Karpov DS, Goncharenko AV.Vaccines against tuberculosis: Problems and Prospects (Review)[J]. Appl Biochem Microbiol, 2020, 56(5): 497-504.
[2] Stagg HR, Lewis JJ, Liu X, et al.Temporal factors and missed doses of tuberculosis treatment: A causal associations approach to analyses of digital adherence data[J]. Ann Am Thorac Soc, 2020, 17(4): 438-449.
[3] 中华医学会结核病学分会. 结核病免疫治疗专家共识(2022年版)[J]. 中华结核和呼吸杂志,2022,45(7):651-666.
[4] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中华传染病杂志,2021,39(12):715-735.
[5] 许晶晶,卢鹏,薛浩,等. 盐城市大丰区高一新生结核潜伏感染筛查及影响因素分析[J]. 华南预防医学,2024,50(5):420-423.
[6] Krishnamoorthy Y, Ezhumalai K, Murali S, et al.Prevalence and risk factors associated with latent tuberculosis infection among household contacts of smear positive pulmonary tuberculosis patients in South India[J]. Trop Med Int Health, 2021, 26(12): 1645-1651.
[7] 中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(第三版)[J]. 中华传染病杂志,2015(10):577-593.
[8] 齐俊英,田德英. 感染性疾病诊疗指南(临床医师诊疗丛书)[M]. 3版. 北京:科学出版社,2013:107-112.
[9] 中华医学会结核病学分会,结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识[J]. 中华结核和呼吸杂志,2017,40(6):419-425.
[10] 中华医学会. 临床诊疗指南·免疫学分册[M]. 北京:人民卫生出版社,2008:1140-1146.
[11] 中国医疗保健国际交流促进会营养与代谢管理分会,中国营养学会临床营养分会,中华医学会糖尿病学分会,等. 中国超重/肥胖医学营养治疗指南(2021)[J]. 中国医学前沿杂志(电子版),2021,13(11):1-55.
[12] 闫俊江. 营养学基础与常见疾病的营养治疗研究[M]. 汕头:汕头大学出版社,2022:217-221.
[13] Henry RT, Jiamsakul A, Law M, et al.Factors associated with and characteristic of HIV/tuberculosis co-infection: A retrospective analysis of SECOND-LINE Clinical Trial Participants[J]. J Acquir Immune Defic Syndr, 2021, 87(1): 720-729.
[14] 谢周华,韦柳迎,董文逸,等. HIV/AIDS合并结核分枝杆菌潜伏感染特征及影响因素分析[J]. 中国热带医学,2022,22(8):739-743.
[15] 蒋泽顺,杨正贵,李江平,等. HIV/AIDS患者结核潜伏感染的影响因素研究[J]. 中国全科医学,2022,25(30):3796-3802.
[16] 熊娜婷,余志康,张国良. T-SPOT.TB、MLR和PLR在活动性肺结核和合并结核潜伏感染的非结核性肺病鉴别诊断中的价值[J]. 华南预防医学,2024,50(3):259-262,266.
[17] 王大刚,李韦杰,金方方,等. EB病毒潜伏感染的HIV/AIDS患者临床特点及免疫特征分析[J]. 中国艾滋病性病,2023,29(4):383-387.
[18] Son H, Mok J, Lee M, et al.Status and determinants of treatment outcomes among new tuberculosis patients in South Korea: A Retrospective Cohort Study[J]. Asia Pac J Public Health, 2021, 33(8): 907-913.
[19] 白若靖,代丽丽,吴昊. 艾滋病抗病毒治疗的研究进展[J]. 北京医学,2021,43(9):850-852.
[20] Radtke KK, Ernest JP, Zhang N, et al.Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: A translational pharmacokinetic-pharmacodynamic modeling study[J]. Antimicrob Agents Chemother, 2021, 65(12): e1705-e01721.
[21] 赵胜男, 陈晓红. HIV-1潜在病毒库的研究进展[J]. 中国艾滋病性病, 2021, 27(5): 557-560.
[22] Spence BC, Bruxvoort K, Munoz-Plaza C, et al.Patient-reported barriers to treatment initiation and completion for latent tuberculosis infection among patients within a large integrated health care system in Southern California[J]. J Public Health Manag Pract, 2023, 29(3): 345-352. |
